Abstract
Exposure of phosphatidylserine on the outer leaflet of the cytoplasmic membrane is an early event during apoptotic cell death and serves as a recognition signal for phagocytes. Usually the clearance of apoptotic cells does not initiate inflammation or immune response. We investigated the immune response in Balb/c mice towards apoptotic human T-cells. Animals injected with apoptotic cells showed significantly reduced humoral immune responses, especially Th1-dependent IgG2a titres, compared to controls immunised with viable cells. However, treatment of apoptotic cells with annexin V (AxV) significantly increased the humoral immune response. AxV binds with high affinity to anionic phospholipids and as a result interferes with the phosphatidylserine recognition by phagocytes. Our results indicate that AxV treatment may be used to increase the efficiency of apoptotic cell-based vaccines, e.g. some tumour vaccines. Cell Death and Differentiation (2000) 7, 911–915
Similar content being viewed by others
Introduction
During the course of pathological conditions cells may die through necrosis involving disruption of membrane integrity, subsequent swelling, and finally cellular lysis. In contrast, cells undergoing apoptosis retain their membrane integrity and are scavenged before they release potentially dangerous contents into the microenvironment. As part of the apoptotic death program cells undergo rapid surface changes such as modification of carbohydrates and exposure of anionic phospholipids especially phosphatidylserine (PS). The latter response is caused by downregulation of the ATP-dependent aminophospholipid translocase, which specifically transports aminophospholipids from the outer to the inner leaflet of the cytoplasmic membrane. Furthermore, a non-specific lipid flipsite, termed scramblase, is activated resulting in an accelerated PS flip-flop.1 It is well established that PS serves as recognition signal for the clearance of apoptotic cells.2,3,4,5 In a recent publication it was shown that preincubation of apoptotic lymphocytes with AxV efficiently blocked the uptake of apoptotic cells by murine peritoneal macrophages, macrophages of the mouse J774 cell line and bone marrow macrophages.6 In addition, this study demonstrated that AxV generally leads to a strong inhibition of apoptotic cell uptake by both activated and non-activated macrophages.6 Furthermore, it was demonstrated that redistribution of PS both on phagocyte and prey is involved in the engulfment of apoptotic cells.7 This paper confirmed the inhibition by annexin V of apoptotic cell uptake.7 In addition, annexin V was shown to decelerate apoptosis in CEM cells by its Ca2+ channel activity.8
Usually engulfment of apoptotic cells induces neither inflammation5 nor an immune response.9 In direct contact to plasma, apoptotic cells may exert procoagulatory and under certain conditions, proinflammatory effects10,11,12 due to de-encryption of tissue factor.13 However, anti-inflammatory and immunomodulatory effects of apoptotic cells on monocytes/macrophages usually dominate, for instance through the interaction of apoptotic cells with CD36 on phagocytes via thrombospondin.14,15
Lectin-like molecules, the vitronectin receptor (CD51/CD61), thrombospondin, CD36,5 as well as CD1416,17 have all been described to be receptors which recognise surface changes on apoptotic cells. CD14 seems to be required for phagocytosis of lymphocytes and necessary for phagocytosis of lipid-symmetric erythrocytes both by non-activated and activated macrophages.1
Since phagocytosis of apoptotic lymphocytes by macrophages is stereospecifically inhibited by phosphatidyl-L-serine liposomes, a specific receptor may be involved in PS recognition.18 This PS-receptor has not been clearly defined yet, however, CD14, CD68, CD3619 have been proposed as candidates. In addition, β2-glycoprotein, the annexins and gas-6 may serve as adaptor proteins.20 Furthermore, a novel receptor defined by monoclonal antibodies elicited by immunisation with TGF-β- and β-glucan-stimulated macrophages was reported to mediate PS-dependent uptake of apoptotic cells.21 (Presented at the 7th Bertine Koperberg Conference on ‘Apoptosis and Autoimmunity’, Nijmegen, June 1999.)
We have recently shown that animals injected with apoptotic human T-cells in comparison to controls injected with viable cells showed significantly decreased humoral immune responses against human T-cells.22 As we demonstrate here, apoptotic cells are a poor immunogen to elicit Th1-dependent IgG2a antibodies. Furthermore, Ronchetti and colleagues recently observed that immunisation with apoptotic cancer cells induced drastically decreased cytotoxic T-cell responses compared to immunisation with living, growth arrested cells.23 These reports indicate that engulfment phagocytosis of apoptotic cells does not lead to efficient antigen presentation and activation of T and B lymphocytes. It is possible that rapid engulfment phagocytosis of apoptotic cells by macrophages may prevent uptake and efficient presentation of apoptotic cell-derived antigens by dendritic cells. Together with an increased production of IL-10 by monocytes after encountering apoptotic cells, these results may explain the poor efficiency of those cancer vaccines containing apoptotic cells.14,23 Therefore, we speculate that surface changes during apoptosis direct apoptotic cells towards phagocytosis by monocytes/macrophages, without induction of either inflammation or an immune response.
AxV which binds with high affinity PS on dying cells efficiently blocks the uptake of apoptotic cells into macrophages in vitro.6,24 To investigate whether the immunogenicity of apoptotic cells can be increased by interfering with PS recognition by phagocytes, we incubated xenogeneic apoptotic cells with AxV prior to injection into mice. AxV treatment markedly increased the immunogenicity of xenogeneic apoptotic cells. Therefore, we concluded that AxV may be useful to increase the efficiency of those cell based vaccines containing apoptotic cells.
Results
AxV specifically binds to PS with a high affinity in a Ca2+-dependent manner.25,26,27 Therefore, AxV is commonly used to detect PS on surfaces of apoptotic cells.28 In addition, AxV has been shown to inhibit phagocytosis of apoptotic cells by human24,29 and mouse macrophages.6 Similarly, in coculture experiments of UV-B irradiated murine macrophages with viable thioglycollate elicited murine macrophages we observed that the addition of chicken AxV resulted in a markedly increased amount of uningested apoptotic cell material (data not shown).
Figure 1 shows the AxV binding of viable vs apoptotic human T-cells used for primary immunisation of Balb/c mice. Approximately 70% of the irradiated T-cells exposed PS as analyzed by AxV-FITC binding, whereas only 10% of the non-irradiated cells were stained with AxV-FITC. Using conventional light microscopy immediately before injection we observed that at least 85% of the UV irradiated cells excluded trypan blue. Therefore, most of the irradiated T-cells displayed an apoptotic phenotype at the time of injection.
In preceding immunisation experiments we compared the human T-cell lines used for immunisation with HUT78 cells as targets for detection of murine antibodies against human T-cells by flow cytofluorometry. No difference was observed between both target cell types (data not shown). In this study we employed HUT78 for quantification of murine antibodies against human T-lymphocytes (a-huL), since they can be grown continuously and independently of restimulation cycles.
To further analyze the reduced immunogenicity of apoptotic cells and to investigate whether masking of PS by AxV can restore the humoral immune response to apoptotic cells, we immunised Balb/c mice with viable vs apoptotic human T-cells. Highly immunogenic xenogeneic cells were used to exclude the possibility of direct antigen presentation by the injected cells to recipient T-cells.30 After primary immunisation of mice with human T-cells, the a-huL antibody titres were low (Figure 2). Animals which had received apoptotic cells displayed reduced a-huL-titres compared to mice injected with viable cells. Co-injection with FA of either viable or apoptotic cells modestly increased a-huL-IgG titres (Figure 2, right).
After booster injection a-huL-IgG-titres (Figure 3, right) were markedly lower in mice which had received apoptotic cells than in mice injected with viable cells (mean fluorescence (MF)-IgG: 32±7.3 and 126±6.3, respectively; P<0.0001). Treatment of apoptotic cells with AxV significantly increased the a-huL-IgG titres (MF-IgG: 89±10; P=0.0015). The a-huL-IgM-titres (Figure 3, left) were only slightly reduced in mice injected with apoptotic cells compared to mice injected with viable cells (MF-IgM: 6±1.4 and 11±3.2, respectively; P=0.036). Therefore, treatment of apoptotic human lymphocytes with AxV largely restored their immunogenicity (Figure 3).
Co-injection with FA of either viable or apoptotic cells modestly increased a-huL-IgG titres (Figure 3, right), whereas a-huL-IgM-titres were only slightly increased. The a-huL-IgG titres were significantly decreased in mice which had received apoptotic cells (MF-IgG: 70±3.6 compared with 156±9.9; P=0.004). Treatment of apoptotic cells with AxV led to significantly increased a-huL-IgG-titres (MF-IgG: 138±4.3 compared to 70±3.6; P<0.0001).
Figure 4 shows that the a-huL-IgG1 and IgG2a titres in mice which had received apoptotic cells were significantly reduced compared to mice injected with viable cells (MF-IgG1: 13±1.1 and 21±2.2 respectively; P=0.010; MF-IgG2a: 5.6±2.0 and 26±3.6 respectively; P=0.0007). While the a-huL-IgG1 titres in mice injected with AxV treated apoptotic cells were only marginally increased, the a-huL-IgG2a titres were more than doubled by AxV treatment, however, this result did not reach statistical significance (P=0.081). Preabsorption of murine sera with AxV did not reduce the a-huL-titres, thereby excluding the possibility that AxV antibodies are responsible for the increased a-huL-titres in mice immunised with AxV treated cells (not shown).
Discussion
Reduced immune responses against apoptotic cells have been observed in an inbred mouse model,9 in Balb/c mice immunised with xenogeneic apoptotic lymphocytes22 and in C57BL/6 mice after immunisation with apoptotic tumour cells.23,24,25,26,27,28,29,30,31 Furthermore, transfusion of viable blood mononuclear cells has been reported to induce IgM, IgG1, and IgG2a anti-donor antibodies resulting in a suppression of subsequent delayed type hypersensitivity reactions, while apoptotic cells led to neither alloimmunisation nor immunosuppression.9
Since alloantigens can be presented to recipient T-cells either directly by donor antigen presenting cells (APC) or indirectly by recipient APC, the mechanism of antibody induction in the murine alloimmunisation experiment can not be defined precisely. To exclude direct presentation, which would be dependent on costimulatory signals from donor APC, we used xenogeneic T-cell lines as the immunogen. In this case a direct presentation appears highly unlikely and an immune response should be exclusively dependent on indirect antigen presentation by murine APC after phagocytosis of the human T-cells. One may speculate that in this system the reduced immunogenicity of apoptotic cells is due to a failure of murine APC to activate T-cells after engulfment of apoptotic cells. In syngeneic and presumably many allogeneic murine systems both direct and indirect antigen presentations are basically possible and could not be clearly distinguished.30
We hypothesise that the engulfment of apoptotic cells by macrophages normally engages a processing pathway which does not result in efficient antigen presentation and/or costimulation with consecutive T-cell activation. To investigate this hypothesis we incubated apoptotic cells with AxV in order to mask PS and thereby to interfere with the PS dependent phagocytosis. The calcium-dependent inhibition of phagocytosis of apoptotic cells by AxV was first described for smooth muscle cells.24 In recent publications it was shown that AxV generally leads to a marked inhibition of the uptake of apoptotic cells by both activated and unactivated macrophages.6,7 Treatment of apoptotic cells with AxV increased their immunogenicity, suggesting that they were able to encounter a pathway leading to both antigen presentation and delivery of costimulatory signals. We speculate that AxV interfered with the PS recognition and the highly efficient engulfment of apoptotic cells by macrophages. Therefore, the uptake and presentation of apoptotic cell material by dendritic cells might be favoured. Recently it was shown that dendritic cells are able to acquire antigens from apoptotic cells23,30,31,32 and elicit a class I-restricted CTL response.33 However, in the presence of macrophages the CTL response was abrogated. The authors suggested that macrophages efficiently engulfing apoptotic cells may degrade the antigen.33 Another explanation for the effect of annexin V on the immunogenicity of apoptotic cells is that under certain circumstances annexin V is able to delay apoptotic cell death by increasing the intracellular Ca2+ concentration.8 However, there are other reports linking the increase of intracellular Ca2+ concentration with augmentation of apoptosis.34
Although a decreased immune response against apoptotic cells could be observed for IgG1 as well as IgG2a, the decrease was more pronounced for the Th1-dependent IgG2a subclass. In addition, AxV treatment predominantly increased the IgG2a response. This argues for a preferential inhibition of the Th1-like responses. Interestingly, we have observed earlier that the presence of apoptotic cells in monocyte cultures can shift the Th1 cytokine secretion pattern towards Th2.14 An alternative explanation for the increased immunogenicity of AxV treated apoptotic cells would be a disruption of the cytoplasmic membrane by AxV resulting in necrosis and release of immunostimulatory or inflammatory mediators,9 thereby providing a yet undefined ‘danger’ signal for the APC.30,31 However, in vitro AxV does not cause cytoplasmic membrane leakage as shown by dye exclusion.28 Furthermore, AxV treatment did not lead to an increased immunogenicity of viable human T-cells (not shown).
Our data may have implications for the development of vaccines which are based on apoptotic cells. For instance, cellular tumour vaccines usually display a poor immunogenicity if the cancer cells are irradiated before injection.35,36 Thereby, irradiation-induced apoptosis may result in a non-inflammatory engulfment by macrophages and, in addition, an anti-inflammatory effect of apoptotic cells on human monocytes/macrophages.14,15 Based on our immunisation experiments with xenogeneic apoptotic cells we assume that treatment with AxV may also increase the immunogenicity of irradiated tumour vaccines.
Taken together our data show that xenogeneic apoptotic cells are poor inducers of humoral immune responses, especially Th1-dependent Ig2a antibodies. Furthermore, we have demonstrated that the immunogenicity of apoptotic cells can be largely restored by AxV treatment.
Materials and Methods
Animals
Balb/c mice were obtained from Charles River Wiga (Sulzfeld, Germany). Six-week-old female mice were used in the experiments.
Cell culture and induction of apoptosis
Human T-cell lines were established from peripheral blood mononuclear cells (PBMC) using phytohemagglutinin (PHA) activation and IL-2. T-cells were maintained and expanded in RPMI 1640 medium (Gibco, Eggenstein, Germany) supplemented with 30% CG medium (Vitromex, Vilshofen, Germany), 5% heat inactivated foetal bovine serum (Gibco, Eggenstein, Germany), gentamycin (100 μg/ml) and recombinant human IL-2 (100 U/ml) (Eurocetus, Frankfurt, Germany) at 37°C and 5% CO2. Every 3 weeks T-cells were restimulated using PHA (1 μg/ml) in the presence of irradiated (30 Gy) heterologous PBMC.
Immunisation
The cloning and the isolation of chicken AxV used in our studies was performed as described elsewhere.26 In one set of experiments Balb/c mice were assigned randomly to three treatment groups (n=6), intraperitoneally injected with viable cells, apoptotic cells or AxV-treated apoptotic cells, respectively. In another set of experiments the cell suspension was mixed with FA (140 μl/ml) immediately before injection (n=4). Seventeen days after the primary immunisation all animals received a booster injection identical to their primary immunisation.
After apoptosis induction by UV-B irradiation (180 mJ/cm2) human T-cells were cultured in medium without IL-2 for another 20 h. The cells were then harvested and washed twice with Ringer's solution. One million cells/ml were incubated in Ringer's solution in the presence or absence of AxV (1.2 μg/ml) on ice for 30 min. Each Balb/c mouse was then injected intraperitoneally with 5×105 cells suspended in 500 μl Ringer's solution without prior washing. At the time of injection more than 90% of these T-cells displayed an apoptotic phenotype according to microscopic evaluation and by propidium iodide staining in the presence of Triton X-100. More than 85% of the cells excluded trypan blue and approximately 70% of these cells had exposed PS as measured by AxV binding. Therefore, most of the cells displayed an early apoptotic phenotype.37 Non-irradiated control cells were cultured in the presence of IL-2, washed twice and resuspended in Ringer solution 30 min before injection. For the detection of PS exposure, 105 cells were stained with 0.5 μl AxV-FITC (Boehringer, Mannheim, Germany) in 500 μl Ringer's solution on ice for 30 min and analyzed by cytofluorometry.
Analysis of sera by flow cytofluorometry
Ten days after each injection, murine sera were collected and stored at −20°C. Preimmune sera and sera from mice injected with Ringer's solution served as negative controls. Murine a-huL were quantified by indirect immunofluorescence using either viable or apoptotic HUT78 cells as well as the T-cell lines used for immunisation. Cells (1.2×105) were incubated with 5 μl mouse serum (diluted 1 : 10 with PBS containing 1% BSA and 0.1% NaN3) for 1 h at 4°C. After washing the cells twice with FACS-PBS 5 μl FITC labelled anti-mouse-IgG, anti-mouse-IgM, anti-mouse-IgG1 or anti-mouse-IgG2a serum was added for 30 min at 4°C. The bound fluorescence was measured using an EPICS XLTM cytofluorometer (Coulter, Hialeah, USA). All data presented in the figures were obtained using viable HUT78 as targets.
Statistical analysis
Results are expressed as means±S.E.M. and statistical significance was analyzed by one-tailed Students' t-test for unpaired data (InStat 2.01, GraphPad Software, San Diego, USA).
Abbreviations
- AxV:
-
annexin-V
- a-huL:
-
anti-human-T-lymphocyte
- APC:
-
antigen presenting cells
- FA:
-
incomplete Freund's adjuvant
- PHA:
-
phytohemagglutinin
- PS:
-
phosphatidylserine
References
Schlegel RA, Krahling S, Callahan MK and Williamson P . 1999 CD14 is a component of multiple recognition systems used by macrophages to phagocytose apoptotic lymphocytes. Cell Death Differ. 6: 583–592
Bratton DL, Fadok VA, Richter DA, Kailey JM, Guthrie LA and Henson PM . 1997 Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J. Biol. Chem. 272: 26159–26165
Verhoven B, Schlegel RA and Williamson P . 1995 Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J. Exp. Med. 182: 1597–1601
Verhoven B, Krahling S, Schlegel RA and Williamson P . 1999 Regulation of phosphatidylserine exposure and phagocytosis of apoptotic T lymphocytes [In Process Citation]. Cell Death Differ. 6: 262–270
Savill J, Fadok V, Henson P and Haslett C . 1993 Phagocyte recognition of cells undergoing apoptosis. Immunol. Today 14: 131–136
Krahling S, Callahan MK, Williamson P and Schlegel RA . 1999 Exposure of phosphatidylserine is a general feature in the phagocytosis of apoptotic lymphocytes by macrophages. Cell Death Differ. 6: 183–189
Marguet D, Luciani MF, Moynault A, Williamson P and Chimini G . 1999 Engulfment of apoptotic cells involves the redistribution of membrane phosphatidylserine on phagocyte and prey. Nat. Cell. Biol. 1: 454–456
Gidon-Jeangirard C, Solito E, Hofmann A, Russo-Marie F, Freyssinet JM and Martinez MC . 1999 Annexin V counteracts apoptosis while inducing Ca(2+) influx in human lymphocytic T cells. Biochem. Biophys. Res. Commun. 265: 709–715
Mincheff MS, Getsov SI and Meryman HT . 1995 Mechanisms of alloimmunization and immunosuppression by blood transfusions in an inbred rodent model. Transplantation 60: 815–821
Mincheff M . 1998 Changes in donor leukocytes during blood storage. Implications on post-transfusion immunomodulation and transfusion-associated GVHD. Vox. Sang. 2: 189–200
Casciola-Rosen L, Rosen A, Petri M and Schlissel M . 1996 Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc. Natl. Acad. Sci. U.S.A. 93: 1624–1629
Reutelingsperger CP and van Heerde WL . 1997 Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell. Mol. Life Sci. 53: 527–532
Greeno EW, Bach RR and Moldow CF . 1996 Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab. Invest. 75: 281–289
Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR and Girkontaite I . 1997 Immunosuppressive effects of apoptotic cells. Nature 390: 350–351
Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY and Henson PM . 1998 Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 101: 890–898
Flora PK and Gregory CD . 1994 Recognition of apoptotic cells by human macrophages: inhibition by a monocyte/macrophage-specific monoclonal antibody. Eur. J. Immunol. 24: 2625–2632
Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL and Gregory CD . 1998 Human CD14 mediates recognition and phagocytosis of apoptotic cells [see comments]. Nature 392: 505–509
Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL and Henson PM . 1992 Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148: 2207–2216
Endemann G, Stanton LW, Madden KS, Bryant CM, White RT and Protter AA . 1993 CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268: 11811–11816
Fadok VA, Bratton DL, Frasch SC, Warner ML and Henson PM . 1998 The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death Differ. 5: 551–562
Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz and Henson PM . 2000 A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature. 405: 85–90
Ponner BB, Stach C, Zoller O, Hagenhofer M, Voll R, Kalden JR and Herrmann M . 1998 Induction of apoptosis reduces immunogenicity of human T-cell lines in mice. Scand. J. Immunol. 47: 343–347
Ronchetti A, Rovere P, Iezzi G, Galati G, Heltai S, Protti MP, Garancini MP, Manfredi AA, Rugarli C and Bellone M . 1999 Immunogenicity of apoptotic cells In vivo: role of antigen load, antigen-presenting cells, and cytokines [In Process Citation]. J. Immunol. 163: 130–136
Bennett MR, Gibson DF, Schwartz SM and Tait JF . 1995 Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine. Circ. Res. 77: 1136–1142
Pfannmuller E, Turnay J, Bertling W and von der Mark K . 1993 Organisation of the chicken annexin V gene and its correlation with the tertiary structure of the protein. FEBS Lett. 336: 467–471
Turnay J, Pfannmuller E, Lizarbe MA, Bertling WM and von der Mark K . 1995 Collagen binding activity of recombinant and N-terminally modified annexin V (anchorin CII). J. Cell Biochem. 58: 208–220
van Heerde WL, de Groot PG and Reutelingsperger CP . 1995 The complexity of the phospholipid binding protein Annexin V. Thromb. Haemost. 73: 172–179
Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST and van Oers MH . 1994 Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84: 1415–1420
Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB and Kalden JR . 1998 Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 41: 1241–1250
Gallucci S, Lolkema M and Matzinger P . 1999 Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5: 1249–1255
Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P, Rugarli C and Manfredi AA . 1998 Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J. Immunol. 161: 4467–4471
Rubartelli A, Poggi A and Zocchi MR . 1997 The selective engulfment of apoptotic bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extracellular calcium. Eur. J. Immunol. 27: 1893–1900
Albert ML, Sauter B and Bhardwaj N . 1998 Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392: 86–89
Nicotera P and Orrenius S . 1998 The role of calcium in apoptosis. Cell Calcium 23: 173–180
Cayeux S, Beck C, Aicher A, Dorken B and Blankenstein T . 1995 Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur. J. Immunol. 25: 2325–2331
Khazaie K, Prifti S, Beckhove P, Griesbach A, Russell S, Collins M and Schirrmacher V . 1994 Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. Proc. Natl. Acad. Sci. U.S.A. 91: 7430–7434
Rovere P, Sabbadini MG, Vallinoto C, Fascio U, Zimmermann VS, Bondanza A, Ricciardi-Castagnoli P and Manfredi AA . 1999 Delayed clearance of apoptotic lymphoma cells allows cross-presentation of intracellular antigens by mature dendritic cells. J. Leukoc. Biol. 66: 345–349
Acknowledgements
We thank Dr. Michael May (Yale University, New Haven, CT, USA) for critical reading of the manuscript. Supported by BMFT KBF 01 GB9403 and Bayerische Forschungsstiftung FORGEN.
Author information
Authors and Affiliations
Corresponding author
Additional information
Edited by A Rosen
Rights and permissions
About this article
Cite this article
Stach, C., Turnay, X., Voll, R. et al. Treatment with annexin V increases immunogenicity of apoptotic human T-cells in Balb/c mice. Cell Death Differ 7, 911–915 (2000). https://doi.org/10.1038/sj.cdd.4400715
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4400715
Keywords
This article is cited by
-
The macrophage-associated prognostic gene ANXA5 promotes immunotherapy resistance in gastric cancer through angiogenesis
BMC Cancer (2024)
-
Mesenchymal stromal cell apoptosis is required for their therapeutic function
Nature Communications (2021)
-
Regulation of efferocytosis as a novel cancer therapy
Cell Communication and Signaling (2020)
-
Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment
Nature Communications (2020)
-
Apoptotic cell clearance in the tumor microenvironment: a potential cancer therapeutic target
Archives of Pharmacal Research (2019)